Cargando…

Rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case report

BACKGROUND: Rhabdomyolysis is a potentially life-threatening disease caused by melting or necrosis of skeletal muscle cells and leakage of muscle components into the bloodstream. It has been reported that the interaction of the HMG-CoA reductase inhibitor rosuvastatin with the renal anemia drug vada...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakurama, Keiki, Iguchi, Yuki, Haruki, Sara, Hata, Yusuke, Hiraga, Madoka, Yumoto, Shinya, Kai, Yutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084597/ https://www.ncbi.nlm.nih.gov/pubmed/37032382 http://dx.doi.org/10.1186/s40780-023-00281-2

Ejemplares similares

Correction to: Rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case report
por: Sakurama, Keiki, et al.
Publicado: (2023)

Rosuvastatin-Induced Rhabdomyolysis: A Case Report
por: Nikalji, Ravindra, et al.
Publicado: (2021)

Fatal Rhabdomyolysis in a COVID-19 Patient on Rosuvastatin
por: Anklesaria, Zafia, et al.
Publicado: (2020)

Rhabdomyolysis induced by rosuvastatin combined with entecavir: a case report
por: Wang, Wen, et al.
Publicado: (2022)

Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease
por: Koury, Mark J., et al.
Publicado: (2022)

Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis
por: Sarnak, Mark J, et al.
Publicado: (2023)

Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open‐label study in Japan
por: Nangaku, Masaomi, et al.
Publicado: (2020)

Rhabdomyolysis caused by an unusual interaction between azithromycin and simvastatin
por: Alreja, Gaurav, et al.
Publicado: (2012)

Clinical Rhabdomyolysis With Acute Kidney Injury Secondary to High-Intensity Rosuvastatin Use: A Case Report
por: Chitralli, Deepak, et al.
Publicado: (2020)

Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents
por: Haase, Volker H, et al.
Publicado: (2019)

Assessing the Carcinogenicity of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl-4-Hydroxylase Inhibitor, in Rodents
por: Kowalski, Heather, et al.
Publicado: (2023)

Sitagliptin and Simvastatin Interaction Causing Rhabdomyolysis and AKI
por: Patel, Chinmay, et al.
Publicado: (2019)

A Pharmacogenomic Dissection of a Rosuvastatin-Induced Rhabdomyolysis Case Evokes the Polygenic Nature of Adverse Drug Reactions
por: Calderon-Ospina, Carlos Alberto, et al.
Publicado: (2020)

Vadadustat, a HIF Prolyl Hydroxylase Inhibitor, Improves Immunomodulatory Properties of Human Mesenchymal Stromal Cells
por: Zielniok, Katarzyna, et al.
Publicado: (2020)

Efficacy and Safety of Vadadustat for Anemia in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis
por: Xiong, Limei, et al.
Publicado: (2022)

Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study
por: Nangaku, Masaomi, et al.
Publicado: (2021)

Rhabdomyolysis Caused by Rhinovirus
por: Tan, Lay Ong, et al.
Publicado: (2016)

Effect of Phosphate Binders and a Dietary Iron Supplement on the Pharmacokinetics of a Single Dose of Vadadustat in Healthy Adults
por: Paulson, Susan K., et al.
Publicado: (2022)

A phase 3, open‐label, single‐arm study of vadadustat for anemia in chronic kidney disease for Japanese patients on hemodialysis not receiving erythropoiesis‐stimulating agents
por: Nangaku, Masaomi, et al.
Publicado: (2021)

Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials
por: Agarwal, Rajiv, et al.
Publicado: (2023)

Rhabdomyolysis Caused by Gefitinib Overdose
por: Obayashi, Shohei, et al.
Publicado: (2021)

Severe rhabdomyolysis induced by co-administration of cocaine and heroin in a 45 years old man treated with rosuvastatin: a case report
por: Mitaritonno, Michele, et al.
Publicado: (2021)

Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe
por: Yamazaki, Daisuke, et al.
Publicado: (2013)

Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects
por: Kim, Chang Hee, et al.
Publicado: (2017)

Clinical characteristics of spinning-induced rhabdomyolysis and other causes of rhabdomyolysis: a comparative study
por: Shroff, Kashyap, et al.
Publicado: (2021)

Current Perspectives on rosuvastatin
por: Hu, Miao, et al.
Publicado: (2013)

A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects
por: Jung, Jin Ah, et al.
Publicado: (2015)

In vivo and In vitro Drug Interactions Study of Glimepride with Atorvastatin and Rosuvastatin
por: Galani, VJ, et al.
Publicado: (2010)

Pharmacokinetic and pharmacodynamic interaction of Rosuvastatin calcium with guggulipid extract in rats
por: Asad, Mohammed, et al.
Publicado: (2021)

Rifaximin as a rare cause of rhabdomyolysis in cirrhosis
por: Rezigh, Alec B., et al.
Publicado: (2018)

Rhabdomyolysis in an HIV cohort: epidemiology, causes and outcomes
por: Koubar, Sahar H., et al.
Publicado: (2017)

An undifferentiated cause of rhabdomyolysis: a case report
por: Patil, Pallavi, et al.
Publicado: (2023)

Rhabdomyolysis secondary to drug interaction between atorvastatin, omeprazole, and dexamethasone
por: Elazzazy, Shereen, et al.
Publicado: (2012)

The etiology of rhabdomyolysis: an interaction between genetic susceptibility and external triggers
por: Kruijt, N., et al.
Publicado: (2020)

Dexmethylphenidate-Induced Rhabdomyolysis by Interaction With Aromatase Inhibitor
por: Huang, Derrick, et al.
Publicado: (2022)

Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO(2)VATE trials
por: Eckardt, Kai-Uwe, et al.
Publicado: (2020)

Rosuvastatin and chronic hepatitis C
por: Yoshida, Eric M.
Publicado: (2011)

Rosuvastatin induced photolocalized purpura
por: Thabouti, Marwa, et al.
Publicado: (2022)

An Unexpected Interaction between Sofosbuvir/Ledipasvir and Atorvastatin and Colchicine Causing Rhabdomyolysis in a Patient with Impaired Renal Function
por: Patel, Shyam, et al.
Publicado: (2016)

Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction
por: Ren, Yizhi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lgoouesqr49kce79bsr82qji7a